Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634049 · ClinicalTrials.gov registry record · Phase 3
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 149
- Enrollment target
NCT00634049 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 149 participants.
The verdict
NCT00634049, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 149 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of isavuconazole in the treatment of renally impaired participants with invasive fungal infections caused by Aspergillus and participants with invasive fungal disease caused by rare fungi.
Interventions
- DRUG isavuconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2008-04-22 |
| Est. Completion | 2016-05-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00634049
The ClinicalTrials.gov registry entry for NCT00634049 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which isavuconazole is the first listed.
NCT00634049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00634049 about?
NCT00634049 is a clinical study titled "Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi". The purpose of this study is to investigate the efficacy and safety of isavuconazole in the treatment of renally impaired participants with invasive fungal infections caused by Aspergillus and participants with invasive fungal disease caused by rare fungi.
What is the current status of trial NCT00634049?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 149 participants. The study started on 2008-04-22. Estimated completion is 2016-05-05.
What interventions are being tested in trial NCT00634049?
The interventions under investigation include: isavuconazole (DRUG).
Who is sponsoring clinical trial NCT00634049?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.